SURMOUNT-1
Tirzepatide Once Weekly for the Treatment of Obesity
Doente / População Intervenção / Exposição Comparação Desfecho
In 2,539 adults with obesity without type 2 diabetes, tirzepatide 5, 10 or 15 mg weekly reduced body weight at 72 weeks compared with placebo.
N
2539
Desenho
Double-blind RCT, 72 weeks
Desfecho
Percent change in body weight
Relevância
3
ResultadoWeight loss −16.0/−21.4/−22.5 % vs −2.4 %; ≥20 % loss in 57 % of the 15 mg group.
Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. 10.1056/NEJMoa2206038
Discussão e crítica
The largest pharmacological weight loss outside bariatric surgery to date — basis of the Zepbound/Mounjaro obesity indication.